CRISPR Therapeutics Announces Oral Presentation of New Data on CTX001, a CRISPR Gene-Edited Medicine for β … – GlobeNewswire (press release)
|
CRISPR Therapeutics Announces Oral Presentation of New Data on CTX001, a CRISPR Gene-Edited Medicine for β …
GlobeNewswire (press release) CTX001 is an investigational CRISPR gene-edited therapy for patients suffering from β-thalassemia and sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high level of fetal hemoglobin (HbF; hemoglobin F) in red … What's Happening To These Stocks? – Vantiv, Inc. (VNTV), CRISPR Therapeutics AG (CRSP) Crispr Therapeutics (CRSP) Rating Lowered to Hold at BidaskClub … The Tyler Dylan-Hyde Sells 21639 Shares of Crispr Therapeutics AG (CRSP) Stock |
